The PROMOMED group of companies has started clinical trials of the Areplivira injection form for the treatment of coronavirus infection, the GK reports. Earlier, the Ministry of Health of the Russian Federation issued permission to conduct phase I studies.
The determination of the safety of the drug produced in the form of lyophilisate for the preparation of infusion solutions will be carried out on the basis of Clinical Hospital No. 3 of the Yaroslavl Region and will last until the end of September 2021.
“After completing all stages of clinical research, Russian doctors will receive an effective drug for the treatment of hospitalized patients with COVID-19, including with a severe course of disease,” the press service of the Civil Code said.
“We are continuing scientific developments in the field of creating innovative effective and safe drugs to combat infections. At the same time, we are expanding and modernizing the capacities of the Biochemist plant in order to ensure stable and guaranteed quality of domestic healthcare with vital medicines, including those aimed at treating the new COVID-19 coronavirus infection, “said Peter Bely, Chairman of the Board of Directors of PROMOMEDA.
At the moment, Areplivir (INN favipiravir) is produced in the form of 40 pieces of tablets in one package. According to Dmitry Pushkar, a member of the consortium of the academic community for the study of coronavirus infection, academician of the Russian Academy of Sciences, etiotropic therapy occupies an important place in COVID-19 therapy.
“Favipiravir is recommended by the Ministry of Health of Russia for the treatment of coronavirus infection of any severity. International data on the effectiveness of combined use of favipiravir with monoclonal antibodies are emerging. If we talk about hospitalized patients, and these are most often patients with a severe current, then the injectable form of favipiravir will, on the one hand, be more convenient to use, on the other, it may allow increasing the effectiveness of therapy, “he said.
“Areplivir” is a drug with directed action against RNA-containing viruses, which include SARS-Cov-2. In the course of clinical studies, which were conducted in 2020 under the guidance of full members of the Russian Academy of Sciences in five medical institutions in Russia, he proved his high effectiveness in treating a new coronavirus infection (ensuring the removal of the virus from the body, improving the lung condition, reducing the risks of a severe current and accelerating recovery). It is part of the priority treatment scheme in the methodological recommendations of the Ministry of Health for the treatment of COVID-19. Included in the VMED list.
